Hematology
Refine search
Biotechnology
Privately-held US cell therapy company Orca Bio today announced the appointment of biopharma veteran Dr Bijan Nejadnik as chief medical officer (CMO). 18 May 2026
Biotechnology
Chinese biotech Akeso is pressing ahead with one of oncology’s most bruised targets, reporting mid-stage data suggesting its anti-CD47 antibody ligufalimab may improve survival outcomes in newly diagnosed acute myeloid leukemia patients unable to receive intensive chemotherapy. 18 May 2026
Pharmaceutical
Significant deal-making news last week included US pharma Rigel acquiring rights to Arvinas and Pfizer’s breast cancer drug Veppanu for up to $405 million, and Hengrui Pharma entered into a deal with Bristol Myers Squibb licensing 13 early-stage oncology and hematology programs to the US major for up to $15.2 billion. In other news, Biogen released mixed Phase II trial results for its investigational cancer drug diranersen, under development with Ionis, and China’s BeOne Medicines gained US Food and Drug Administration (FDA) approval for its Beqalzi in mantle cell lymphoma. 17 May 2026
Pharmaceutical
The Food and Drug Administration (FDA) yesterday approved Inqovi, an oral combination of decitabine and cedazuridine tablets from Taiho Oncology, with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML). 14 May 2026
Pharmaceutical
Bristol Myers Squibb’s Eliquis (apixaban) is on course for one of the largest single-asset revenue collapses in pharmaceutical history. 14 May 2026
Biotechnology
The European Commission (EC) has granted marketing authorization to expand the approved indication for Pfizer’s Hympavzi (marstacimab) to include patients 12 years of age and older weighing at least 35 kg with hemophilia A (congenital factor VIII [FVIII] deficiency) with FVIII inhibitors or hemophilia B (congenital factor IX [FIX] deficiency) with FIX inhibitors. 13 May 2026
Biotechnology
Servier Ventures, the VC fund created by the French drugmaker, has selected Cytospire Therapeutics for its first investment. 13 May 2026
Pharmaceutical
Hengrui Pharma's Hong Kong-listed shares surged significantly to around HK$76.00 - up over 13% - after the company announced a massive licensing accord with Bristol-Myers Squibb. 12 May 2026
Biotechnology
CSL Ltd shares are being hammered after the Australian biotech released another painful update to the market, with the stock closing down 16% at A$100.75, having fallen as much as 20%. 11 May 2026
Biotechnology
UK clinical-stage biotech CellCentric has announced the completion of an oversubscribed $220 million Series D financing. 7 May 2026
Biotechnology
US biotech Vertex Pharmaceuticals today announced that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel). 6 May 2026
Pharmaceutical
US biopharma company Veradermics last week reported encouraging top-line Phase II/III results for its hair loss treatment VDPHL01. On the M&A front, Eli Lilly announced it is to acquire Ajax Therapeutics for up to $2.3 billion along with its hematology candidate AJ1-110915. Also, Chiesi announced a takeover of USA-based KalVista Pharma and its Ekterly to expand its rare diseases portfolio. US biotech AnaptysBio won a favorable court ruling in its dispute with GSK/Tesaro over cancer drug Jemperli. 3 May 2026
Biotechnology
Hemab Therapeutics Holdings, a Phase III-ready biotech developing blood coagulation disorder treatments, has announced terms for its initial public offering (IPO). 1 May 2026
Pharmaceutical
US pharma major Eli Lilly delivered a standout first quarter of 2026, with financial results comfortably exceeding market expectations. 30 April 2026
Pharmaceutical
US pharma major Bristol Myers Squibb has reported better-than-expected financial results for the first quarter of 2026, with revenues rising 3% year-on-year to $11.49 billion, ahead of analyst forecasts of around $10.9 billion. 30 April 2026
Biotechnology
US pharma giant Pfizer has announced positive topline results from the Phase III MagnetisMM-5 study of Elrexfio (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment. 30 April 2026
Biotechnology
The New England Journal of Medicine (NEJM) has published 26-week results from the Phase III FRONTIER2 trial evaluating the efficacy and safety of once-monthly and once-weekly Mim8 (denecimig) in adults and adolescents 12 years of age and older with hemophilia A (congenital Factor VIII (FVIII) deficiency), with or without FVIII inhibitors. Investigational denecimig is a bispecific antibody Factor VIIIa (FVIIIa) mimetic, designed for routine prophylaxis to help the body form blood clots. 30 April 2026
Biotechnology
Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) who have had an insufficient response to at least one previous glucocorticoid treatment has been accepted for review and granted priority review by the China National Medical Products Administration (NMPA). 29 April 2026
Biotechnology
Gilead Sciences and its Kite Oncology subsidiary have announced that the European Medicines Agency (EMA) has approved a Type II variation to the Summary of Product Characteristics (SmPC) for its approved chimeric antigen receptor (CAR) T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel). 28 April 2026
Biotechnology
Swedish Orphan Biovitrum, also known as Sobi, reported first-quarter revenue in line with expectations, while adjusted operating profit (EBITA) exceeded analyst forecasts. 28 April 2026
Biotechnology
Privately-held US cell therapy company Orca Bio today announced the appointment of biopharma veteran Dr Bijan Nejadnik as chief medical officer (CMO). 18 May 2026
Biotechnology
Chinese biotech Akeso is pressing ahead with one of oncology’s most bruised targets, reporting mid-stage data suggesting its anti-CD47 antibody ligufalimab may improve survival outcomes in newly diagnosed acute myeloid leukemia patients unable to receive intensive chemotherapy. 18 May 2026
Pharmaceutical
Significant deal-making news last week included US pharma Rigel acquiring rights to Arvinas and Pfizer’s breast cancer drug Veppanu for up to $405 million, and Hengrui Pharma entered into a deal with Bristol Myers Squibb licensing 13 early-stage oncology and hematology programs to the US major for up to $15.2 billion. In other news, Biogen released mixed Phase II trial results for its investigational cancer drug diranersen, under development with Ionis, and China’s BeOne Medicines gained US Food and Drug Administration (FDA) approval for its Beqalzi in mantle cell lymphoma. 17 May 2026
Pharmaceutical
The Food and Drug Administration (FDA) yesterday approved Inqovi, an oral combination of decitabine and cedazuridine tablets from Taiho Oncology, with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML). 14 May 2026
Pharmaceutical
Bristol Myers Squibb’s Eliquis (apixaban) is on course for one of the largest single-asset revenue collapses in pharmaceutical history. 14 May 2026
Biotechnology
The European Commission (EC) has granted marketing authorization to expand the approved indication for Pfizer’s Hympavzi (marstacimab) to include patients 12 years of age and older weighing at least 35 kg with hemophilia A (congenital factor VIII [FVIII] deficiency) with FVIII inhibitors or hemophilia B (congenital factor IX [FIX] deficiency) with FIX inhibitors. 13 May 2026
Biotechnology
Servier Ventures, the VC fund created by the French drugmaker, has selected Cytospire Therapeutics for its first investment. 13 May 2026
Pharmaceutical
Hengrui Pharma's Hong Kong-listed shares surged significantly to around HK$76.00 - up over 13% - after the company announced a massive licensing accord with Bristol-Myers Squibb. 12 May 2026
Biotechnology
CSL Ltd shares are being hammered after the Australian biotech released another painful update to the market, with the stock closing down 16% at A$100.75, having fallen as much as 20%. 11 May 2026
Biotechnology
UK clinical-stage biotech CellCentric has announced the completion of an oversubscribed $220 million Series D financing. 7 May 2026
Biotechnology
US biotech Vertex Pharmaceuticals today announced that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel). 6 May 2026
Pharmaceutical
US biopharma company Veradermics last week reported encouraging top-line Phase II/III results for its hair loss treatment VDPHL01. On the M&A front, Eli Lilly announced it is to acquire Ajax Therapeutics for up to $2.3 billion along with its hematology candidate AJ1-110915. Also, Chiesi announced a takeover of USA-based KalVista Pharma and its Ekterly to expand its rare diseases portfolio. US biotech AnaptysBio won a favorable court ruling in its dispute with GSK/Tesaro over cancer drug Jemperli. 3 May 2026
Biotechnology
Hemab Therapeutics Holdings, a Phase III-ready biotech developing blood coagulation disorder treatments, has announced terms for its initial public offering (IPO). 1 May 2026
Pharmaceutical
US pharma major Eli Lilly delivered a standout first quarter of 2026, with financial results comfortably exceeding market expectations. 30 April 2026
Pharmaceutical
US pharma major Bristol Myers Squibb has reported better-than-expected financial results for the first quarter of 2026, with revenues rising 3% year-on-year to $11.49 billion, ahead of analyst forecasts of around $10.9 billion. 30 April 2026
Biotechnology
US pharma giant Pfizer has announced positive topline results from the Phase III MagnetisMM-5 study of Elrexfio (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment. 30 April 2026
Biotechnology
The New England Journal of Medicine (NEJM) has published 26-week results from the Phase III FRONTIER2 trial evaluating the efficacy and safety of once-monthly and once-weekly Mim8 (denecimig) in adults and adolescents 12 years of age and older with hemophilia A (congenital Factor VIII (FVIII) deficiency), with or without FVIII inhibitors. Investigational denecimig is a bispecific antibody Factor VIIIa (FVIIIa) mimetic, designed for routine prophylaxis to help the body form blood clots. 30 April 2026
Biotechnology
Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) who have had an insufficient response to at least one previous glucocorticoid treatment has been accepted for review and granted priority review by the China National Medical Products Administration (NMPA). 29 April 2026
Biotechnology
Gilead Sciences and its Kite Oncology subsidiary have announced that the European Medicines Agency (EMA) has approved a Type II variation to the Summary of Product Characteristics (SmPC) for its approved chimeric antigen receptor (CAR) T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel). 28 April 2026
Biotechnology
Swedish Orphan Biovitrum, also known as Sobi, reported first-quarter revenue in line with expectations, while adjusted operating profit (EBITA) exceeded analyst forecasts. 28 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze